Product Reports Resources Pricing Login Book a demo

Acceleron Pharma

Biotech & Life Sciences · Cambridge, United States · Founded 2004 · IPO 2013

Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

Valuation $12B
Revenue $135M

Investors

12 investors on Acceleron Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 11 investors entered at this stage
Harvard University
Flagship Pioneering
OrbiMed
Polaris Partners
Celgene
MPM BioImpact
Venrock
Salk Institute for Biological Studies
Bessemer Venture Partners
Foresite Capital
Advanced Technology Ventures

Global footprint

Where Acceleron Pharma has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown
Web traffic by country
50 monthly visits
across markets
🇺🇸 United States0%
Top 1 markets shown

Talent graph

The shape of Acceleron Pharma's talent

Dealroom maps Acceleron Pharma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Acceleron Pharma's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$328M patent portfolio · 101 active families

Estimated portfolio value
$328M
2.9% of market cap · 1.7× smaller than top peer ChemoCentryx ($550M)
101 active patent families
Where Acceleron Pharma innovates AntagonistAntiendomysial antibodiesBiochemistryCell biologyDisease

Where Acceleron Pharma concentrates vs peers

Each axis is a top-10 topic across Acceleron Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Acceleron Pharma

An AI-synthesized read of the highest-engagement posts about Acceleron Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Acceleron Pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.